Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial.
Julian PanesSeverine VermeireGeert R D'HaensSilvio DaneseFernando MagroMaciej NazarManuela Le BarsMarjolein LahayeLioudmila NiIvana BravatàDaniel R GayaLaurent Peyrin BirouletAxel U Dignassnull nullPublished in: United European gastroenterology journal (2023)
Independent of treatment strategy (T2T or SoC), ustekinumab was effective in improving HRQoL measurements and WPAI over a period of 2 years.